No information is available on the clinical use of osimertinib during breastfeeding. Because osimertinib is 95% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 48 hours and it might accumulate in the infant. The drug also has 2 active metabolites that have not been studied in breastmilk. The manufacturer recommends that breastfeeding be discontinued during osimertinib therapy and for 2 weeks after the final dose.
关于奥希替尼在母乳喂养期间的临床应用尚无可用信息。由于奥希替尼与血浆蛋白的结合率为95%，乳汁中的含量可能较低。然而，其半衰期约为48小时，可能会在婴儿体内蓄积。该药物还有2种活性代谢产物，尚未在母乳中进行研究。制造商建议在奥希替尼治疗期间及最后一剂后2周内停止母乳喂养。
